Patents Assigned to BEIJING MEDINTELL BIOMED CO., LTD
  • Patent number: 11718880
    Abstract: The present invention discloses a marker and a diagnosis method for the noninvasive diagnosis of myocardial infarction. According to the method disclosed by the present invention, second-generation sequencing and QPCR methods are used to find that there are significant differences in the expression of ING1, RAE1, DOCK10, KDSR, IVD, and MAEA in the blood of patients with myocardial infarction and normal subjects, that is, the expression of ING1, RAE1, DOCK10, KDSR, IVD and MAEA can be detected to determine whether the subjects suffer from myocardial infarction. According to the correlation between the two, the present invention develops a kit for the diagnosis of the myocardial infarction, and the kit is used for the diagnosis of the myocardial infarction by detecting the expression of ING1, RAE1, DOCK10, KDSR, IVD and MAEA. The diagnostic kit can be used for the early diagnosis of diseases, and has wide application prospect clinically.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: August 8, 2023
    Assignee: BEIJING MEDINTELL BIOMED CO., LTD
    Inventors: Chenggang Yang, Shuguang Li